CN111344568B - 预测对免疫疗法的反应 - Google Patents
预测对免疫疗法的反应 Download PDFInfo
- Publication number
- CN111344568B CN111344568B CN201880072673.4A CN201880072673A CN111344568B CN 111344568 B CN111344568 B CN 111344568B CN 201880072673 A CN201880072673 A CN 201880072673A CN 111344568 B CN111344568 B CN 111344568B
- Authority
- CN
- China
- Prior art keywords
- cd45ro
- cells
- cell
- live
- distribution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000004044 response Effects 0.000 title claims abstract description 104
- 238000009169 immunotherapy Methods 0.000 title description 3
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 41
- 210000004027 cell Anatomy 0.000 claims description 248
- 238000009826 distribution Methods 0.000 claims description 127
- 238000006243 chemical reaction Methods 0.000 claims description 113
- 239000000090 biomarker Substances 0.000 claims description 66
- 238000012360 testing method Methods 0.000 claims description 57
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 52
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 49
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 39
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 39
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 37
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 37
- 102100036302 C-C chemokine receptor type 6 Human genes 0.000 claims description 35
- -1 CLA Proteins 0.000 claims description 35
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 claims description 35
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 35
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 35
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims description 35
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 32
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 30
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 28
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 28
- 102100033016 Integrin beta-7 Human genes 0.000 claims description 28
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 28
- 108010021315 integrin beta7 Proteins 0.000 claims description 28
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 27
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 27
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 27
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 claims description 24
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 24
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims description 24
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 claims description 24
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims description 24
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 claims description 24
- 238000004458 analytical method Methods 0.000 claims description 23
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 22
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims description 22
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 22
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 22
- 102100027207 CD27 antigen Human genes 0.000 claims description 22
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 claims description 22
- 102100031512 Fc receptor-like protein 3 Human genes 0.000 claims description 22
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 22
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 22
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 22
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 claims description 22
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 22
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 22
- 101000777558 Homo sapiens C-C chemokine receptor type 10 Proteins 0.000 claims description 22
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 22
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 claims description 22
- 101000846910 Homo sapiens Fc receptor-like protein 3 Proteins 0.000 claims description 22
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 22
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 22
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 22
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 22
- 102100022297 Integrin alpha-X Human genes 0.000 claims description 22
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 22
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 22
- 210000001616 monocyte Anatomy 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 21
- 201000001441 melanoma Diseases 0.000 claims description 20
- 102000004190 Enzymes Human genes 0.000 claims description 15
- 108090000790 Enzymes Proteins 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 210000000822 natural killer cell Anatomy 0.000 claims description 14
- 239000003112 inhibitor Substances 0.000 claims description 11
- 230000036961 partial effect Effects 0.000 claims description 11
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 9
- 210000004443 dendritic cell Anatomy 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 8
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 7
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 7
- 229960002621 pembrolizumab Drugs 0.000 claims description 7
- 210000004180 plasmocyte Anatomy 0.000 claims description 7
- 210000003289 regulatory T cell Anatomy 0.000 claims description 7
- 230000003993 interaction Effects 0.000 claims description 6
- 229960003301 nivolumab Drugs 0.000 claims description 6
- 102000009410 Chemokine receptor Human genes 0.000 claims description 5
- 108050000299 Chemokine receptor Proteins 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 5
- 102000006495 integrins Human genes 0.000 claims description 5
- 108010044426 integrins Proteins 0.000 claims description 5
- 230000001413 cellular effect Effects 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 206010027406 Mesothelioma Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 208000023747 urothelial carcinoma Diseases 0.000 claims description 3
- 210000000601 blood cell Anatomy 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 29
- 201000010099 disease Diseases 0.000 abstract description 22
- 230000002519 immonomodulatory effect Effects 0.000 abstract description 13
- 208000035475 disorder Diseases 0.000 abstract description 7
- 239000000523 sample Substances 0.000 description 77
- 230000003902 lesion Effects 0.000 description 53
- 238000011156 evaluation Methods 0.000 description 10
- 208000037821 progressive disease Diseases 0.000 description 10
- 239000002955 immunomodulating agent Substances 0.000 description 9
- 229940121354 immunomodulator Drugs 0.000 description 9
- 102000001398 Granzyme Human genes 0.000 description 7
- 108060005986 Granzyme Proteins 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 7
- 238000002591 computed tomography Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000002595 magnetic resonance imaging Methods 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 238000004163 cytometry Methods 0.000 description 5
- 230000002584 immunomodulator Effects 0.000 description 5
- 238000010801 machine learning Methods 0.000 description 5
- 239000000376 reactant Substances 0.000 description 5
- 229940045513 CTLA4 antagonist Drugs 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000002771 cell marker Substances 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
- 102100038078 CD276 antigen Human genes 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 2
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 1
- 206010051696 Metastases to meninges Diseases 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 206010025226 lymphangitis Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 210000005088 multinucleated cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 108010027322 single cell proteins Proteins 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70521—CD28, CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Ecology (AREA)
- Physiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017903703 | 2017-09-12 | ||
| AU2017903703A AU2017903703A0 (en) | 2017-09-12 | Predicting responses to immunotherapy | |
| PCT/AU2018/050988 WO2019051542A1 (en) | 2017-09-12 | 2018-09-12 | PREDICTING RESPONSES TO IMMUNOTHERAPY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111344568A CN111344568A (zh) | 2020-06-26 |
| CN111344568B true CN111344568B (zh) | 2024-05-28 |
Family
ID=65722268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880072673.4A Active CN111344568B (zh) | 2017-09-12 | 2018-09-12 | 预测对免疫疗法的反应 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200271641A1 (ja) |
| EP (1) | EP3682234A4 (ja) |
| JP (1) | JP7350747B2 (ja) |
| KR (1) | KR102664228B1 (ja) |
| CN (1) | CN111344568B (ja) |
| AU (1) | AU2018333276A1 (ja) |
| CA (1) | CA3074751A1 (ja) |
| WO (1) | WO2019051542A1 (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021092220A1 (en) * | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| WO2021092221A1 (en) * | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| US20230263905A1 (en) | 2020-04-29 | 2023-08-24 | Imgt Co, Ltd. | Sonosensitive liposome and method for preparing same |
| CN112881684A (zh) * | 2021-01-18 | 2021-06-01 | 北京晶科瑞医学检验实验室有限公司 | 一种预测免疫治疗效果的试剂盒 |
| JP7368678B1 (ja) | 2023-04-26 | 2023-10-25 | イミュニティリサーチ株式会社 | Ｃｄ４＋ｔ細胞集団中の特定の細胞亜集団の相対量の測定方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103399150A (zh) * | 2005-11-04 | 2013-11-20 | 贝克曼考尔特公司 | 用于血癌分析与临床处理的细胞抗原及靶信号转导蛋白的复合分布 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090311214A1 (en) * | 2008-06-11 | 2009-12-17 | University Of Maryland, Baltimore | Compositions and methods for the innate immune response pathway |
| WO2016073760A1 (en) * | 2014-11-05 | 2016-05-12 | The Regents Of The University Of California | Methods for stratifying non-responders to therapies that block pd1/pdl1 axis |
| WO2017053250A1 (en) * | 2015-09-21 | 2017-03-30 | Merck Sharp & Dohme Corp. | Antibody that binds to human programmed death ligand 2 (pd-l2) and uses thereof |
| US10969392B2 (en) * | 2015-12-10 | 2021-04-06 | Vanderbilt University | Methods and systems for predicting response to immunotherapies for treatment of cancer |
| EP3571507A1 (en) * | 2017-01-19 | 2019-11-27 | The Regents of The University of California | Methods of identifying and treating patient populations amenable to cancer immunotherapy |
| WO2018147291A1 (en) * | 2017-02-07 | 2018-08-16 | Saitama Medical University | Immunological biomarker for predicting clinical effect of cancer immunotherapy |
-
2018
- 2018-09-12 WO PCT/AU2018/050988 patent/WO2019051542A1/en unknown
- 2018-09-12 CA CA3074751A patent/CA3074751A1/en active Pending
- 2018-09-12 JP JP2020535277A patent/JP7350747B2/ja active Active
- 2018-09-12 CN CN201880072673.4A patent/CN111344568B/zh active Active
- 2018-09-12 US US16/646,483 patent/US20200271641A1/en active Pending
- 2018-09-12 EP EP18855890.2A patent/EP3682234A4/en active Pending
- 2018-09-12 AU AU2018333276A patent/AU2018333276A1/en active Pending
- 2018-09-12 KR KR1020207010362A patent/KR102664228B1/ko active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103399150A (zh) * | 2005-11-04 | 2013-11-20 | 贝克曼考尔特公司 | 用于血癌分析与临床处理的细胞抗原及靶信号转导蛋白的复合分布 |
Non-Patent Citations (5)
| Title |
|---|
| An immune-active tumor microenvironment favors clinical response to ipilimuma;Rui-Ru Ji et al;《 Cancer Immunol Immunother》;20121231;1019–1031 * |
| Julia K. Tietze et al.The proportion of circulating CD45RO+CD8+ memory cells is correlated with clinical response in melanoma atients treated with ipilimumab.《,European Journal of Cancer》.2016,268-279. * |
| Julia K. Tietze et al.The proportion of circulating CD45ROþCD8þmemory T cells is correlated with clinical response in melanoma patients treated with ipilimumab.《European Journal of Cancer》.2017,268-279. * |
| Rui-Ru Ji et al.An immune-active tumor microenvironment favors clinical response to ipilimuma.《 Cancer Immunol Immunother》.2012,1019–1031. * |
| Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma;Adil I. Daud,et al.;《The Journal of Clinical Investigation》;20160930;3447-3452 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018333276A1 (en) | 2020-03-12 |
| US20200271641A1 (en) | 2020-08-27 |
| KR102664228B1 (ko) | 2024-05-09 |
| EP3682234A4 (en) | 2021-05-19 |
| JP2020533608A (ja) | 2020-11-19 |
| EP3682234A1 (en) | 2020-07-22 |
| CA3074751A1 (en) | 2019-03-21 |
| CN111344568A (zh) | 2020-06-26 |
| JP7350747B2 (ja) | 2023-09-26 |
| KR20200052356A (ko) | 2020-05-14 |
| WO2019051542A1 (en) | 2019-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111344568B (zh) | 预测对免疫疗法的反应 | |
| Prat et al. | Immune-related gene expression profiling after PD-1 blockade in non–small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma | |
| EP3639172B1 (en) | Systems and methods for identifying cancer treatments from normalized biomarker scores | |
| Forget et al. | Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome | |
| Jacquelot et al. | Predictors of responses to immune checkpoint blockade in advanced melanoma | |
| Pauken et al. | Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment | |
| Bonfiglio et al. | Genetic and phenotypic attributes of splenic marginal zone lymphoma | |
| Gribben | How I treat CLL up front | |
| Chen et al. | A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade | |
| Ikeguchi et al. | CSF and clinical data are useful in differentiating CNS inflammatory demyelinating disease from CNS lymphoma | |
| Friedman et al. | Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses | |
| Alame et al. | The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling | |
| Winkler et al. | SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer | |
| Steier et al. | Single-cell multiomic analysis of thymocyte development reveals drivers of CD4+ T cell and CD8+ T cell lineage commitment | |
| EP3717915B1 (en) | A system and method for classifying cancer patients into appropriate cancer treatment groups and compounds for treating the patient | |
| Parsons et al. | Phase II single-arm study to assess trastuzumab and vinorelbine in advanced breast cancer patients with HER2-negative tumors and HER2-positive circulating tumor cells | |
| Russo et al. | PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1< 50%: a multiomics analysis | |
| Meireson et al. | Immune monitoring in melanoma and urothelial cancer patients treated with anti-PD-1 immunotherapy and SBRT discloses tumor specific immune signatures | |
| Liu et al. | Predicting patient outcomes after treatment with immune checkpoint blockade: A review of biomarkers derived from diverse data modalities | |
| Attia et al. | Evaluation of prognostic variables in chronic lymphocytic leukemia and association with disease stage | |
| Griffiths et al. | Cancer cells communicate with macrophages to prevent T cell activation during development of cell cycle therapy resistance | |
| CN114354931B (zh) | 脾肿大在确定肿瘤患者免疫检查点抑制剂治疗疗效中的应用 | |
| US20240085417A1 (en) | Peripheral blood phenotype linked to outcomes after immunotherapy treatment | |
| Li et al. | High expression of the ANXA3 gene promotes immune infiltration and improves tumor prognosis in ovarian serous carcinoma using bioinformatics analyses | |
| Chen et al. | Clinical and biological features of mantle cell lymphoma patients with co-expression of CD10 and BCL-6: a retrospective study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |